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Abstract
At least one third of all cases of epithelial ovarian
cancer are associated with the production of ascites,
although its effect on tumor cell microenvironment
remains poorly understood. This study addresses the
effect of the heterologous acellular fraction of ovarian
cancer–derived ascites on a cell line (OV-90) derived
from the chemotherapy-naı¨ve ovarian cancer patient.
Ascites were assayed for their effect on cell invasion,
growth, and spheroid formation. When compared to
either no serum or 5% serum, ascites fell into one
of two categories: stimulatory or inhibitory. RNA from
OV-90 cells exposed to selected ascites were arrayed
on an Affymetrix HG-U133A GeneChip. A supervised
analysis identified a number of differentially expressed
genes and quantitative polymerase chain reaction vali-
dation based on OV-90 cells exposed to 54 indepen-
dent ascites demonstrated that stimulatory ascites
affected the expression of ISGF3G, TRIB1,MKP1, RGS4,
PLEC1, and MOSPD1 genes. In addition, TRIB1 ex-
pression was shown to independently correlate with
prognosis when its expression was ascertained in an
independent set of primary cultures established from
ovarian ascites. The data support the validity of the
strategy to uncover molecular events that are associ-
ated with tumor cell behavior and highlight the impact
of ascites on the cellular and molecular parameters of
ovarian cancer.
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Introduction
Ovarian cancer is the fifth leading cause of cancer-related
deaths in the Western world, the second most common
gynecological cancer, and the leading cause of death from
gynecological malignancies. The most common form of cancer
of the ovary is epithelial ovarian cancer (EOC). EOCs originate
either from the normal ovarian surface epithelium itself or from
the crypts and inclusion cysts on the surface epithelium [1].
Ovarian carcinomas can spread by local extension, lymphatic
invasion, intraperitoneal implantation, hematogenous dissem-
ination, and/or transdiaphragmatic passage. In the commonly
observed intraperitoneal dissemination, malignant cells appear
to implant anywhere over peritoneal surfaces though mainly in
sites of stasis along the peritoneal fluid circulation.
At least one third of ovarian cancer patients present with
ascites [2,3], a generally voluminous exudative fluid with a cel-
lular fraction consisting mainly of ovarian cancer cells, lympho-
cytes, and mesothelial cells. The neoplastic cells in the ascites
are present either as single cells, as aggregates, or as spher-
oids, and may contribute to the spread of cancer to secondary
sites. Indeed, it has been demonstrated that ascites spheroids
adhere to extracellular matrix through b1 integrins, indicating
that this process may play a role in the dissemination of the
disease [4]. The acellular fraction of ascites is known to harbor
angiogenic factors such a vascular endothelial growth factor
[5] and growth factors such as the epidermal growth factor [6],
lysophosphatidic acid [7], and transforming growth factor (TGF)
family members [8,9] among others. How this acellular frac-
tion affects the tumor microenvironment, and specifically how it
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affects the cellular and molecular properties of tumor cells per
se is still a matter of debate [10,11]. Indeed, the recent resur-
gence of intraperitoneal-based chemotherapies highlights the
importance of understanding this important component of the
disease [12–14]. Recently, a targeted approach demonstrated
the ability of ascites to modulate the expression of urokinase
plasminogen activator, its receptor, and integrins, and these
modifications in expression were associated with changes in
the cellular behavior of ovarian cancer cell lines [15].
In the present study, we conducted a comprehensive
analysis of the effect of ascites on the growth characteristics
of the OV-90 ovarian cancer cell line, which we have pre-
viously described [16]. This EOC cell line, derived from the
cellular fraction of ascites from a chemotherapy-naı¨ve pa-
tient, has been characterized by morphological, immunohis-
tochemical, cytogenetic, and molecular analyses including
gene expression profiles [16,17] and was shown to har-
bor mutations in genes implicated in ovarian cancer such as
tumor protein p53 (TP53), cyclin-dependent kinase inhibitor
1A (CDNK2A), and TGF-RII. In addition to characterizing
the cellular effects of ascites, a DNA microarray approach
was used to assess differences in gene expression in OV-90
cell line grown in the presence or absence of serum, as
well as in the presence of ascites without serum. Statistical
analysis was used to identify differentially expressed genes
that correlated with cellular invasion for the OV-90 cell line.
Candidate genes were further validated on both arrayed
RNA and an extended test set using quantitative polymerase
chain reaction (Q-PCR), and their association with survival
was tested in an independent set of primary cultures derived
from patients with ovarian ascites.
Materials and Methods
Cell Culture, Clinical Material, and Patients
The OV-90 cell line was maintained in OSE media con-
sisting of 50:50 medium 199:105 (Sigma-Aldrich, St. Louis,
MO) supplementedwith 10% fetal bovine serum (FBS), 2.5 mg/
ml amphotericin B and 50 mg/ml gentamicin [18]. Following
appropriate consent, ascites were collected at the time of
clinical intervention at the Centre Hospitalier de l’Universite´ de
Montre´al (Montreal, QC, Canada). Ascites were centrifuged at
2500 rpm for 5 minutes. The acellular fractions were stored at
20jC and tested within 6 months of reception. The protein
concentration in ascites fluid was measured by the Bradford
assay (Bio-Rad, Hercules, CA). Histopathology, grade, and
stage of ovarian tumors were assigned according to the Inter-
national Federation of Gynecology and Obstetrics criteria. Of
the 54 ascites included in our study on invasion, two thirds
were from patients diagnosed with papillary serous adeno-
carcinomas and most presented with stage IIIC and grade 3
disease (Table 1). One third of samples were from patients
who had already received chemotherapy prior to surgery. The
presence of neoplastic cells in ascites was determined from
pathology reports. Table 2 describes the 28 ovarian cancer
patients diagnosed with accompanying ascites that were
included in the survival analysis.
In Vitro Invasion Assay
Cellular invasion was assayed by determining the ability
of cells to invade a synthetic basement membrane (Matrigel;
Becton-Dickinson, Bedford, MA). Polycarbonate membranes
(8-mm pore size) of the upper compartment of Transwell
culture chambers were coated with 0.4 mg/ml Matrigel. The
upper compartment was filled with OSE media containing 1%
FBS and the lower compartment was filled with OSE media
either with no serum, with 5% FBS, or with 5% of the indicated
ascites. For inactivation, ascites were heated for 10minutes at
100jC to denature proteins. Ovarian cancer cells were trypsi-
nized and resuspended in OSE media containing 1% FBS.
The cell suspension (20  103 cells/well) was placed in the
upper compartment. Then, cells were incubated at 37jC and
allowed to invade through the Matrigel barrier for 24 hours.
Following incubation, membranes were fixed with methanol
and stained (Giemsa; Sigma-Aldrich). Noninvading cells were
removed using a cotton swab, whereas invading cells on the
underside of the membrane were counted using an inverted
microscope. All experiments were performed at least twice.
Cell Proliferation
Two thousand cells were plated either with no serum,
with 5% FBS, or with 5% of the indicated ascites in six-well
plates and incubated at 37jC. At defined intervals, cells were
trypsinized and cell viability was assessed by a Trypan Blue
exclusion assay. Cell numbers were evaluated using a hemato-
cytometer. Each experiment was performed in triplicate.
Spheroid Formation
Spheroids were formed using a modification of the hang-
ing droplet method [19]. Briefly, 4  103 cells were resus-
pended in 15 ml of OSE media supplemented either with 5%
FBS, with 5% of the indicated ascites, or without serum, and
then placed on the cover of a 150-mm tissue culture plate.
The cover was placed over a plate that contained 15 ml of
OSE to prevent dehydration of the hanging droplet. Spheroid
formation was monitored after 4 days and representative
spheroids were photographed.
RNA Extraction
Total RNA was extracted with a reagent (TRIzol; Gibco/
BRL, Life Technologies, Inc., Grand Island, NY) as recom-
mended by the manufacturer. RNAwas extracted from tumor
cells grown to 80% confluence in 100-mm Petri dishes. RNA
quality was assessed using a 2100 Bioanalyzer with the RNA
6000 Nano LabChip kit (Agilent Technologies, Mississauga,
ON, Canada) according to the manufacturer’s protocol.
Microarray Analysis
Hybridization assays and data collection were performed
at the McGill University and Genome Quebec Innovation
Centre (Montreal, Canada). Briefly, 20 mg of total RNA from
each sample was reverse-transcribed using an oligo-dT
primer containing a T7 RNA polymerase binding site. In vitro
transcription was performed on this cDNA and the resulting
cRNA was biotinylated through incorporation of biotinylated
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dUTP and dCTP. Samples were fragmented in 40 mM Tris–
acetate, 100 mM potassium acetate, and 30 mM MgCl2 (pH
8.1) at 95jC to reduce secondary structure. A total of 15 mg of
cRNA was hybridized to an Affymetrix HG-U133A GeneChip
array (Santa Clara, CA), washed, stained, and scanned with
a Hewlett Packard Gene Array scanner (Palo Alto, CA) and
.CEL files were normalized based on a quantile method.
Gene expression profiles were analyzed using R (www.
r-project.org), a statistical programming language, and Bio-
conductor [20], an open source software library for the
analyses of genomic data based on R. Background subtrac-
tion, normalization (quantile normalization), and expression
value calculations were performed using the justGCrma
function available as part of Bioconductor’s gcrma pack-
age. Bioconductor’s genefilter package was used to filter
out genes with insufficient variation in expression across all
samples tested. Expression values retained after this filtering
process presented intensities greater than 100 U in at least
Table 1. Clinical Characteristics of Patients from Which Ascites Were Obtained.
Ascites Age Histopathology Grade Stage Neoplastic Cells in Ascites Prior Chemotherapy Clinical Intervention Associated with Ascites Collection
A1185(2)* 82 PSA G3 IIIC Yes Yes Secondary cytoreduction
A1301 49 SA G3 IIIC Yes No Primary biopsy
A1317 60 PSA G3 IV No Yes Primary surgery
A1318 52 PSA G2 IIIC Yes No Primary surgery
A1322 71 PSA G3 IIIC Yes No Primary surgery
A1322(2) 71 PSA G3 IIIC Yes Yes Secondary cytoreduction
A1330 48 SA G3 IIIC Yes No Primary surgery
A1337 45 PSA G3 IIIC Yes No Primary surgery
A1369 60 PSA G3 IIIC Yes No Primary surgery
A1369(2) 60 PSA G3 IIIC Yes Yes Secondary cytoreduction
A1396 54 PSA G2 IIIC Yes No Primary surgery
A1406 49 PSA G2 IIIC N/S Yes Secondary cytoreduction
A1464 63 PSA G3 IIIC Yes No Primary surgery
A1483 74 PSA G3 IIIC Yes No Primary surgery
A1519 73 CCA G3 IV N/S No Primary surgery
A1526 50 PSA G2 IIIC Yes Yes Secondary cytoreduction
A1526(2) 50 PSA G2 IIIC Yes Yes Secondary cytoreduction
A1592 35 MCA G3 IIIC N/S No Primary surgery
A1607 59 SA GB IB No No Primary surgery
A1610 72 PSA G3 IIIC Yes No Primary surgery
A1611 45 MA GB IA No No Primary surgery
A1613 76 SA G3 IIIC No No Primary surgery
A1642 79 SA G3 IIB Yes No Primary surgery
A1717 45 PSA G2 IIIC N/S No Primary surgery
A1739 64 MA N/S N/S N/S No Primary surgery
A1778 87 PSA G3 IV Yes No Primary surgery
A1793 55 SA G3 IIIC No No Primary surgery
A1801 65 PSA G2 IIIC Yes No Primary surgery
A1810 62 PSA G2 IIIC Yes No Primary surgery
A1813 55 PSA G3 IIIC Yes No Primary surgery
A1830 56 PSA G3 IIIC Yes No Primary surgery
A1835 69 PSA G3 IIIC Yes No Primary surgery
A1876 44 PSA G3 IIIC No No Primary surgery
A1884 69 PSA G3 IV Yes No Primary surgery
A1891 62 PSA G3 IIIC No No Primary surgery
A1922 52 PSA G3 IIIC Yes No Primary surgery
A1927 48 PSA G3 IIIC Yes No Primary surgery
A1931 67 PSA G3 IIIC Yes No Primary surgery
A1946 75 PSA G3 IIIC Yes No Primary surgery
A1998 70 UA N/S N/S Yes Yes N/S
A1998(2) 70 UA N/S N/S Yes Yes N/S
A2069 63 MCA G3 IIIC Yes No Primary surgery
A2070 78 SA G3 IIIC Yes No Primary surgery
A2085 65 PSA G3 IIIC N/S Yes Secondary cytoreduction
A2085(2) 65 PSA G3 IIIC N/S Yes Secondary cytoreduction
A2085(3) 65 PSA G3 IIIC N/S Yes Secondary cytoreduction
A2090 76 UA N/S IIIC Yes Yes N/S
A2093 62 PSA G3 IV Yes Yes Secondary cytoreduction
A2093(2) 62 PSA G3 IV Yes Yes Secondary cytoreduction
A2774 42 EA G3 IB No No Primary surgery
A2775 49 PSA G2 IIIC Yes No Primary surgery
A2834 63 PSA G3 IIIC Yes No Primary surgery
A2912 54 PSA G3 IIIC Yes No Primary surgery
A2965 71 MCA G3 IIIC Yes No Primary surgery
PSA, papillary serous adenocarcinoma; SA, serous adenocarcinoma; MA, mucinous adenocarcinoma; MCA, mixed cell adenocarcinoma; CCA, clear cell
adenocarcinoma; UA, undifferentiated adenocarcinoma; EA, endometrioid adenocarcinoma; N/S, not specified.
Ascites further characterized in this study are in bold.
*Denotes second and third ascites collected from patient with the same number.
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two samples and a log base 2 scale of at least 0.2 for
the interquartile range across all tested samples. Differ-
entially expressed genes were identified using the limma
package, which estimates the fold-change between prede-
fined groups by fitting a linear model and using an empirical
Bayes method to moderate standard errors of the estimated
log-fold changes for expression values from each probe set.
Quantitative PCR
cDNA synthesis was prepared using the SuperScript
First-Strand Synthesis System for reverse transcription–
polymerase chain reaction (Invitrogen Life Technologies,
Carlsbad, CA) according to the manufacturer’s instruction.
Reverse transcription–polymerase chain reaction was per-
formed on 2 mg of total RNA using 2.5 ml of the random
hexamer solution. Samples were diluted 1:10 in water prior
to Q-PCR. Positive and negative controls were included in
all experiments.
Q-PCRwas performed using theRotor-gene 3000 (Corbett
Research, Montreal Biotech Inc., Montreal, QC, Canada).
Quantitect SYBR Green PCR (QIAGEN Inc., Mississauga,
ON, Canada) was used for labeling in a final volume of 25 ml
containing 5 ml of sample cDNA and 10 pg of the different
primers and reactions performed as described by the manu-
facturer. Experiments were repeated at least twice. Serial
dilutions (1:5) were performed to generate a standard curve
for each gene tested to define the efficiency of the Q-PCR
reaction and a melt curve was done to confirm the speci-
ficity of the reaction. We used the Pfaffl analysis method to
measure the relative quantity of gene expression [21]. The
algorithm is defined by R = (Etarget)
DCp target(control  sample)/
(Eref)
DCp ref(control  sample), where R is the relative expression
ratio, E is the efficiency of the PCR reaction, and DCp is the
difference of the Ct (crossing point of the sample at a given
threshold). The reference gene, ActinB, was selected based
on its stable expression in all samples by microarray analysis.
Moreover, Q-PCR confirmed its appropriateness because no
significant statistical differences were noted among the sam-
ples. The first sample (with 5% FBS) served as the reference
sample in each experiment. The mean value of the Ct from
replicates was used to calculate R. Marker expression was
evaluated in the OV-90 cell line either with no serum, with 5%
FBS, or with 5% of the indicated ascites, under the same con-
ditions used to evaluate the invasion potential of the OV-90
cell line. For each marker, a Pearson correlation was calcu-
lated between the scored invasion result (1 < 100% and 2 z
100% of invasion) and the scored genes expression (1 <
median and 2 z median).
Statistical Analysis
Univariate Cox proportional hazard regression, Kaplan-
Meier survival plots, and log-rank tests were performed to
determine the significance of markers’ ability to predict the
survival of EOC patients (Table 2). The expression threshold
used in the log-rank test that gave the best sensitivity–
specificity values was established based on the receiver op-
erating characteristics (ROC) curves. We used the ROC and
SURVIVAL packages from R version 2.4.0 (Vienna, Austria).
The Spearman correlation coefficient test (two-tailed)
was used to estimate the correlation between the invasion
rates and clinical data and gene expression. Statistical analy-
ses were performed with SPSS software 11.0 (SPSS Inc.,
Chicago, IL).
Results
Effect of Ascites on OV-90 Invasive Potential
To address the interactions among elements found within
the peritoneal tumor environment, we characterized the
effect of a large panel of ascites (Table 1) on the ability of
an aggressive EOC cell line (OV-90) to stimulate invasion in
an in vitro assay. Media containing 5% of ascites (acellular
fraction) from patients with ovarian cancer was added to the
lower chamber of Transwell plates containing micropore fil-
ters precoated with Matrigel and OV-90 cells were added to
the upper chamber. The potential for ascites to affect OV-90
invasion was scored in comparison to media supplemented
with 5% FBS (Figure 1A). OV-90 is capable of invasion in
Matrigel assay in presence of 5% FBS (Figure 1). A large
number of ascites led to an inhibition of OV-90 cell invasion
compared to cells in the presence of FBS. A lower, but still
important number of ascites was more stimulatory for inva-
sion than the FBS control. We assessed the correlation be-
tween the invasion rates of ascites and clinical parameters
Table 2. Patients’ Cohort with Ovarian Cancer and Accompanying Ascites,
for Survival Analyses.
Patients Death Survival (months) Histopathology
90 Yes 0 UA
513 No 37 SA
595 Yes 11 PSA
665 Yes 32 PSA
747 Yes 9 SA
866 No 9 PSA
889 Yes 51 SA
892 No 67 PSA
893 Yes 46 EA
899 No 5 SA
908 Yes 11 PSA
926 Yes 54 PSA
944 No 60 PSA
960 Yes 16 PSA
962 No 72 EA
976 Yes 0 CCA
980 No 26 PSA
993 No 13 SA
999 No 43 MA
1005 No 12 PSA
1012 Yes 3 EA
1035 No 41 CCA
1127 Yes 45 PSA
1129 Yes 16 CCA
1193 Yes 6 PSA
1330 No 13 SA
1830 No 6 PSA
1946 Yes 0 PSA
UA, undifferentiated adenocarcinoma; SA, serous adenocarcinoma; PSA, papil-
lary serous adenocarcinoma; EA: endometrioid adenocarcinoma; CCA, clear
cell adenocarcinoma; MA, mucinous adenocarcinoma.
Patients died following the progression of the disease, except for patients 976
and 1946, death was due to myocardium infarction and digestive hemorrhage.
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available for patients: age, grade, stage, presence of neo-
plastic cells, and chemotherapy, but no significant correlation
was observed (Table 1).
The acellular fraction of 10 independent EOC ascites
(A1317, A1318, A1322, A1322(2), A1337, A1592, A1835,
A1946, A2085, and A2090; Table 1) was selected for further
characterization based on their ability to invade. The invasive
potential was again compared to a 5% FBS control. In OV-90
cells, it should be noted that there is no difference in the
invasion rate with or without 5% FBS and thus the classifi-
cation of ascites as being either inhibitory or stimulatory is
independent of the effect of serum. Inhibitory ascites reduce
the invasion rate compared to either no serum or 5% FBS,
whereas stimulatory ascites results from a higher number of
cells able to cross a Matrigel barrier in comparison to con-
trols. Ascites A1592, A1946, A2085, and A2090 induced an
invasion rate greater to the one observed in the presence
or the absence of FBS. A1317, A1318, A1322, A1322(2),
A1337, and A1835 diminished OV-90 cell invasion potential
(Figure 1B). These effects were not due to differences in
protein concentration of each ascites because correcting for
the amount of protein did not affect the overall patterns
observed (data not shown).
Effect of Ascites on OV-90 Growth
To determine the effect of ascites on proliferation rates, 10
ascites were selected and tested for their ability to alter the
growth potential of OV-90 cells compared to a 5% FBS
control (Figure 2). OV-90 cells were incubated for 2 days in
media supplemented either with no serum, with 5% FBS, or
with 5% of the indicated ascites and cell growth was evalu-
ated by a Trypan Blue exclusion assay. The highest growth
rates were observed with exposure to FBS, as well as
A1835, A1946 or A2085, whereas the remaining ascites
samples conferred variable but lower growth rates. In partic-
ular, OV-90 exhibited lower growth rate in the presence of the
A1337 and A1322(2) ascites compared to those observed
with no serum. We noted that after 24 hours of incubation,
the time used to monitor invasion, no statistically significant
differences in the growth rate were observed (with one
exception). This suggests that the monitored invasive effects
are not a simple reflection of cell growth.
Effect of Ascites on OV-90 Spheroid Formation
We have previously demonstrated that the OV-90 cells
are able to grow as large compact spheroids [19]. Because
the relation between these three-dimensional structures and
invasive potential remains poorly defined, we determined the
effect of ascites on the formation of in vitro spheroids. For
Figure 1. Effect of ascites on the invasion of the ovarian cancer cell line OV-90. The invasive potential of OV-90 (solid bars) was determined by its ability to invade
a synthetic basement membrane after 24 hours compared to 5% FBS (%Invasion*). (A) Effects of 54 ascites on the invasive potential of the cell line. (B) Invasion
profile of OV-90 with OSE medium in the absence or presence of 5% FBS or with 5% of those ascites selected for gene expression analysis.
Figure 2. Effect of ascites on the proliferation of the OV-90 ovarian cancer
cell line. On day 0, 2  105 cells were incubated in media supplemented
either with no serum, with 5% FBS, or with 5% ascites and the cell growth
was evaluated with a Trypan Blue exclusion assay at 24 and 48 hours. Note
that, with one exception, there were no statistically significant differences in
growth after 24 hours in the different tested conditions. The asterisk denotes
a statistical significance (P < .05).
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this purpose, the OV-90 cell line was incubated either in the
absence of serum, in 5% FBS, or in 5% of ascites. The
formation of spheroids was monitored after 4 days. As shown
in Figure 3, the OV-90 cell line formedmultiple very small and
nonreproducible spheroids from drop to drop in the absence
of FBS, which is consistent with previous findings [19]. In the
presence of FBS or ascites A1317 and A1592, however, OV-
90 formed large (approximately 500 mm in diameter) and
compact spheroids. This was reproducible from drop to drop
with one unique spheroid of similar size formed in each drop.
Although cell scattering around spheroids was observed, it
was not significantly different between spheroids generated
in the presence of different ascites. The ability for different
ascites to induce large and compact spheroid formation was
also confirmed with ascites A1318, A1322, A1322(2), A1337,
A1835, A1946, A2085, and A2090, which gave similar
results (Figure W1). Therefore, the ability of ascites to
stimulate spheroid formation did not correlate with the inva-
sion potential of the tested ascites.
Ascites Invasive Phenotype Characterization
Ascites that stimulated or inhibited OV-90 cell invasion
were combined to determine which effect is the most pre-
dominant (Figure 4A). We selected one stimulatory (A2090)
and two inhibitory (A1369 and A1526) ascites. When stimula-
tory and inhibitory ascites were added together (5% A2090 +
5% A1369 or 5% A2090 + 5% A1526), we observed that
the invasion rate was not significantly different compared
to the presence of inhibitory ascites alone. This result sug-
gests that the inhibitory ascites have a predominant impact
on invasion of OV-90 cells compared to a stimulatory as-
cites. This effect was not due to an increased concentration
of ascites in the assay as adjusting individually tested as-
cites to 10% had no effect on the invasive phenotype (data
not shown).
To determine if this predominant effect is protein-dependent,
inhibitory ascites were boiled at 100jC for 10 minutes before
being tested on OV-90 cells (Figure 4B). The results showed
that protein inactivation abolished the inhibitory effect of
the two selected ascites (A1369 and A1526). These com-
bined results suggest that inhibition of OV-90 cell invasion is
protein-based and that the inhibitory effect is stronger than
the stimulatory effect.
Modification of Gene Expression Induced By Ascites
in OV-90 Cells
To identify potential molecular players in invasion regu-
lated by ascites, gene profiling was performed using Affy-
metrix HG-U133A GeneChip arrays with RNA extracted from
OV-90 cells after 24 hours of exposure to either no serum, to
5% FBS, or to 5% of 1 of 10 different ascites (A1317, A1318,
A1322, A1322(2), A1337, A1592, A1835, A1946, A2085,
and A2090).
For supervised analysis purposes, two groups were cre-
ated for comparison. The group that stimulated invasion
(referred here as GSTIMUL group) included samples with
no FBS, with 5% FBS, or with 5% of the four ascites that
stimulated OV-90 cell invasion (A1592, A1946, A2085, and
A2090). An inhibitory group (referred here as GINHIB group)
Figure 4. In vitro invasion assay with the ovarian cancer cell line OV-90. (A) Effect of simultaneous exposure to ascites that stimulate or inhibit the invasion of OV-
90. Note that the inhibitory effect appears to be dominant. (B) Proteins of ascites A1369 and A1526 were inactivated by heating and their effect on the invasion of
OV-90 was evaluated. Note that ascites no longer maintain their inhibitory effect.
Figure 3. Effect of ascites on spheroid formation. Spheroids were formed using
a modification of the hanging droplet method. Cells were incubated with OSE
media supplemented either with no serum, with 5% FBS, or with 5% of the
indicated ascites. Spheroid formation was monitored after 4 days. All pictures
were taken at a magnification of 100.
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containing the six ascites that inhibited cell invasion (A1317,
A1318, A1322, A1322(2), A1337, and A1835) was also
defined. Expression analysis identified 243 probe sets to
be differentially expressed (P V .1) between the GSTIMUL
and GINHIB groups (Table W1).
Differential Expression Validation of Selected
Candidates By Q-PCR
As differences in expression are subtle but tended to be
statistically significant, it was important to validate the value
of the cutoff selected. For this purpose, we selected genes
with different P values (Table 3) to test the robustness of their
association with invasion. Table 3 describes the seven can-
didate genes upregulated in the GSTIMUL group [dickkopf
homolog 1 (Xenopus) (DKK1), regulator of G-protein sig-
naling 4 (RGS4), interferon-stimulated transcription factor 3,
gamma 48 kDa (ISGF3G), tribbles homolog 1 (Drosophila)
(TRIB1), MAP kinase phosphatase 1 (MKP1), cyclooxy-
genase 2 (COX2), and motile sperm domain containing 1
(MOSPD1)] and two candidate genes upregulated in the
GINHIB group [plectin 1, intermediate filament binding pro-
tein 500 kDa (PLEC1) and myristoylated alanine-rich protein
kinase C substrate (MARCKS)] that were selected for fur-
ther validation. Q-PCR was used to validate the differential
expression of selected candidates in RNA derived from
OV-90 cells exposed individually to the entire panel of
54 ascites (Table 1). The relative expression ratio (R) of
each gene, based on the Pfaffl method (see Materials and
Methods section for details), was quantified and, for each
experiment, the median ratio was calculated and the results
scored. Pearson correlations were then calculated for each
candidate correlating ascites invasion effects (stimulatory or
inhibitory) and scored gene expression, as shown in Table 4.
The scored gene expression of RGS4, ISGF3G, TRIB1,
MKP1, MOSPD1, and PLEC1 correlated significantly with
the ascites’ invasion effects, but not the expression of DKK1,
COX2, and MARCKS. These results also suggest that an
extensive validation of candidates identified in the super-
vised analysis by Q-PCR is warranted to uncover the rich-
ness of genes implicated in the invasive process.
Survival
To evaluate the prognosis potential of the selected gene
candidates RGS4, ISGF3G, TRIB1, MKP1, MOSPD1, and
PLEC1, we sought to access the expression of these genes
in samples derived from patients with ovarian ascites. There-
fore, we extracted expression values from a microarray
analysis of RNA extracted from 28 primary cultures derived
from the cellular fraction of ascites from ovarian cancer pa-
tients (Table 2). Univariate Cox regression analysis showed
a strong association only between TRIB1 gene expression
and overall survival (P = .0007). Using a threshold deter-
mined by ROC analysis, a Kaplan-Meier curve coupled to a
log-rank test identified the presence of two patient groups
and high TRIB1 expression was associated with a poorer
survival rate (log-rank P = .005) (Figure 5).
Discussion
Although ascites is a common phenotype in ovarian cancer,
the origin of malignant ascitic fluid and its relationship to the
developing tumor is still poorly understood. The observation
that ascites is often associated with the most invasive
malignant tumors indirectly supports the notion that ascites
is involved in the progression of ovarian cancer [22] presum-
ably by favoring the dissemination of malignant cells within
the peritoneal cavity. Contributing to the development of
ascites are soluble factors produced by tumor cells that are
known to increase vascular permeability and induce angio-
genesis [5,23]. Although ascitic soluble factors such as
chemokines, angiogenic factors, and growth factors have
been implicated in ovarian cancer cell invasion [24–26], the
combined effect of these factors in the progression of ovarian
cancer has not been addressed. In this study, we assessed
the effects of ascites on the invasion, proliferation, spheroid
formation, and gene expression of the cell line OV-90 [16].
The overall aim was to determine how ascites alters its
microenvironment and thus the biological characteristics of
ovarian cancer cells.
Using a Matrigel-based invasion assay, 54 individual
ascites showed varying effects on OV-90 cell invasion with
some ascites being either poorly stimulatory or inhibitory
compared to serum. This data is in contrast to other ascites
that strongly stimulated the invasive capacity of this cell line.
The varying invasive effects were not associated with total
protein concentration in ascites, because adjusting for this
factor did not affect the overall effect of invasion (data not
shown). The inhibitory effect of ascites was lost when
samples were heated, suggesting that the effect was due
to protein inactivation rather than other soluble factors.
Moreover, no correlation between the effect of ascites on
invasion and chemotherapy, received prior to ascites collec-
tions, was noted.
Correlation of the invasion assay results with two other
parameters, cellular proliferation and spheroid formation,
was assessed because stimulation of cell growth could lead
to bias in the number of cells counted in the upper chamber
of the Transwell and because formation of compact spher-
oids may interfere with the ability to pass through the
polycarbonate membrane pores. The initial characterization
studies focused on 10 ascites possessing either stimulatory
or inhibitory properties. Although cell growth and spheroid
formation were influenced to some extent by ascites, neither
parameter was strongly associated with OV-90 invasive
capacity. In general, higher doubling times or saturation
densities with ascites in comparison to serum were not
observed. These findings are similar to results obtained by
independent analyses of the PEO.36, OVHS, and SKOV-3
ovarian cancer cell lines [15,27], suggesting that although
ascites might affect the in vitro biological characteristics
(e.g., survival) of tumor cells, it does not necessarily contrib-
ute to the proliferation of tumor cells.
To investigate the molecular events associated with the
invasive effect of ascites, global RNA gene expression from
OV-90 cells in the presence or absence of serum or ascites
was characterized. As expected, differential gene expression
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patterns occurred in treated cells from which we determined a
subset of differentially expressed genes that correlated with
invasion potential. Interestingly, most of the genes within this
subset have not been previously linked to ovarian cancer in-
vasion. Among these genes, DUSP1/MKP1, TRIB1, ISGF3g/
IRF-9, RGS4, MOSPD1, and PLEC1 overexpression was
validated by Q-PCR in a large set of samples confirming the
potential role of these genes in the cellular invasion process.
The gene signature of ascites-stimulated OV-90 cells
reinforces the role of the mitogen-activated protein kinase
(MAPK) pathway in the invasion process. Extracellular sig-
nal–regulated protein kinase (ERK) MAPKs have already
been shown to be involved in invasion through the activa-
tion of metalloproteinase [28–31] and Snail [32] promoters.
Here we observed altered expression of two genes impli-
cated inkinase regulation, namelyTRIB1andMKP1.TRIB1 is a
serine/threonine kinase protein interacting with the mitogen-
activated protein kinase 4. The effect of this interaction on
MAPK pathway activity is unknown but TRIB1 overexpres-
sion inhibits Ras- and mitogen-activated protein kinase
kinase/extracellular signal–regulated protein kinase kinase
1–mediated activator protein–1 activation whereas ERK
activation is enhanced. On the other hand, MKP1, the MAP
kinase phosphatase 1, is the target of the ERKs. This phos-
phorylation does not modify the intrinsic ability of MKP1 to
dephosphorylate p44MAPK, but leads to the stabilization of
the protein. Although these results suggest that ascites may
regulate the invasion potential of OV-90 cells through TRIB1
overexpression that activates ERKs, the microarray data
do not show Snail and metalloproteinase overexpression in
OV-90 cells stimulated with invasive ascites. This does not
rule out that other downstream targets of the ERK pathway
could be affected. Indeed, RGS4, a member of the regulator
of G protein signaling family, has been involved in the in-
hibition of MAPK and protein kinase B (PKB/AKT) activation
in neuroblastoma cells as well as ERKs activation induced
by angiotensin and endothelin but not by serum stimula-
tion [33,34]. Moreover, RGS4 has also been associated
with invasion and motility of glioma cells [35]. Our results
are consistent with this latter observation because a direct
correlation between RGS4 gene expression and invasion
was determined.
The gene signature of ascites-stimulated OV-90 also re-
vealed an altered regulation of the ISGF3g/IRF9 and
MOSPD1 genes. ISGF3 is an interferon-dependent tran-
scription factor involved in resistance to chemotherapeu-
tic agents [36,37] but not in any known cellular invasion
process. MOSPD1 belongs to the transmembrane MSP-
containing protein family. Its role in mammals is largely un-
known but it is thought to be involved in the formation of
protein–protein networks [38]. These networks have not yet
been associated with cellular invasion so far but our results
suggest a new role for these proteins in cancer progression.
One explanation for the lack of association of the majority
of the genes identified in this study with the invasive potential
of neoplastic cells is perhaps not surprising because few
studies have attempted to determine the direct effect of as-
cites on ovarian cancer cells. In addition, meta-analyses of
gene profiling studies between normal and cancerous cells
are difficult to compare with our study due to various factors
such as differences in model systems, use of different plat-
forms, and a dearth of clinical data accompanying the stud-
ies including whether tumor formation was accompanied
with ascites formation. Consequently, over the long term,
we favor a functional approach, taking advantage of the
model systems we have developed coupled with in vitro
and in vivo assays, to determine the precise role of promising
candidate genes in the process of invasion.
In summary, this study revealed novel candidate genes
that may play an important role in ovarian cancer cell inva-
sion and potentially affect clinical outcomes. This study has
also begun to define the importance and subtleties of as-
cites in modulating the tumor microenvironment and sug-
gests that both positive and negative regulators of tumor
behavior may be present in ascites. Further functional as-
says are required to determine their exact role in this bio-
logical process. Continued evaluation of ascites on EOC
behavior is warranted and a comprehensive systems bi-
ology approach is required to fully understand the complex
Table 4. Correlation between Invasion and Genes Expression.
Genes Pearson Correlation P
DKK1 0.096 .468
RGS4 0.302* .019
ISGF3G 0.377y .003
TRIB1 0.302* .019
MKP1 0.397y .002
COX2 0.206 .114
MOSPD1 0.357y .005
MARCKS 0.226 .082
PLEC1 0.322* .019
Pearson correlations were calculated between scored invasion results (1 <
100% of invasion and 2 z 100% of invasion) and scored genes expression
(1 < median and 2 z median) for the six candidates quantified by Q-PCR.
*Correlation is significant at the level 0.05.
yCorrelation is significant at the level 0.01.
Figure 5. Relation between TRIB1 expression and cumulative survival of pa-
tients with ovarian cancer in the context of concomitant ascites. The threshold
was determined by ROC analysis. Kaplan-Meier graphical representation of
survival curve illustrates the poor survival associated with a high expression of
TRIB1 (P < .005).
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interactions within the peritoneum that influence EOC pro-
gression and metastasis.
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Figure W1. Effect of ascites on spheroid formation. Spheroids were formed using a modification of the hanging droplet method. Cells were incubated with OSE
media supplemented either with no serum, with 5% FBS, or with 5% ascites. Spheroid formation was monitored after 4 days.
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